As of November 6, 2026, GH Research plc is a publicly traded company (Nasdaq: GHRS); its largest reported holder is Lynx1 Capital Management LP, with 19.3% on Schedule 13G/A of August 14, 2026, then Fidelity (FMR) (9.4%). The largest insider holding is Florian Schonharting, a director, with 14,824,419 shares (23.9% of shares outstanding), per Form 3 of April 1, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in GH Research plc? See the free Snapshot first.
Free to see. No signup.
Is GH Research plc a real, registered company?
- GH Research PLC files with the SEC under CIK 1855129 (its SEC filings).
- Its shares are listed under the ticker GHRS on Nasdaq (SEC company record).
- Incorporated in L2; business address in Dublin 2, L2, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under GH RESEARCH PLC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are GH Research plc's owners and officers?
GH Research plc: business address in Dublin 2, L2; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 9.4% |
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 7.1% |
| Schedule 13G/A, 2026-08-14 | Lynx1 Capital Management LP | 19.3% |
| Schedule 13G/A, 2026-05-18 | Lynx1 Capital Management LP | 17.4% |
| Schedule 13G/A, 2026-05-15 | Lynx1 Capital Management LP | 15.2% |
| Schedule 13G/A, 2026-02-17 | Lynx1 Capital Management LP | 16.8% |
| Schedule 13G/A, 2025-11-14 | Lynx1 Capital Management LP | 13.9% |
| Schedule 13G/A, 2025-11-14 | Terwey Theis H | 2.9% |
| Schedule 13G/A, 2025-08-14 | Terwey Theis H | 7.6% |
| Schedule 13G/A, 2025-08-14 | Ra Capital Management, L.P. | 12.4% |
| Schedule 13G/A, 2025-08-06 | Fmr LLC | 8.2% |
Questions about who owns GH Research plc
Who owns GH Research plc?
On this page, 3 holders' latest ownership filings report 5% or more of GH Research plc: Lynx1 Capital Management LP (19.3%, Schedule 13G/A, filed 2026-08-14), Fmr LLC (9.4%, Schedule 13G/A, filed 2026-11-05) and Ra Capital Management, L.P. (7.1%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of GH Research plc?
By the share each holder's latest filing reports, the largest holders of GH Research plc on this page are Lynx1 Capital Management LP (19.3%), Fmr LLC (9.4%) and Ra Capital Management, L.P. (7.1%).
When did Lynx1 Capital Management LP buy into GH Research plc?
The filings give report dates, not purchase dates. The earliest filing from Lynx1 Capital Management LP on this page is the Schedule 13G/A, filed 2025-11-14, reporting 13.9%; its latest, Schedule 13G/A filed 2026-08-14, reports 19.3%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on GH Research plc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on GH Research plc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on GH Research plc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own GH Research plc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 14,824,419 shares (23.9% of shares outstanding) (Form 3, 2026-04-01).
- , the ireland and a director: 118,354 shares (0.19% of shares outstanding) (Form 3, 2026-04-02).
- , a director: 45,509 shares (0.07% of shares outstanding) (Form 3, 2026-04-02).
- , a director: 14,600 shares (0.02% of shares outstanding) (Form 3, 2026-04-17).
- , a director: 2,432 shares (0.00% of shares outstanding) (Form 3, 2026-04-02).
Shares outstanding: 62,029,395 as of 2025-12-31, from the company's latest SEC cover page.
How much has GH Research plc raised?
No fundraising or offering filing from GH Research plc is on file with us.
Keep reading
More on GH Research plc and the records around it.
GH Research plc elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Stoke Therapeutics, Inc. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/gh-research